tiprankstipranks
Spruce Biosciences: Cash equivalents as of December 31 $96M
The Fly

Spruce Biosciences: Cash equivalents as of December 31 $96M

Cash and cash equivalents as of December 31 were approximately $96M. Based on the company’s current operating plan, operating and capital expenditures are funded into the first half of 2025. Common shares outstanding as of December 31 were 41.0 M.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on SPRB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles